Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | LPL | P06858 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29561231 | 1.00 | CA2 (0.39) | CA2TP53TAAR1SMN1; SMN2LMNA | |
| Iodide SCHEMBL4336770 | 0.98 | SMN1; SMN2 (0.39) | CA2TP53TAAR1SMN1; SMN2LMNA | |
| Bromide SCHEMBL11435482 | 0.98 | CA2 (0.38) | CA2TP53TAAR1SMN1; SMN2LMNA | |
| Bromide SCHEMBL10844297 | 0.81 | CA2 (0.35) | CA2TP53TAAR1SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL11428178 | 0.78 | LPL (0.35) | CA2TP53TAAR1SMN1; SMN2CYP2A6 | |
| SCHEMBL8723606 | 0.78 | KDM4E (0.36) | CA2TP53TAAR1SMN1; SMN2LMNA | |
| SCHEMBL1105765 | 0.76 | LMNA (0.43) | SMN1; SMN2LMNAKDM4EMEN1APOBEC3A | |
| Bromide SCHEMBL10858949 | 0.75 | SMN1; SMN2 (0.44) | CA2TP53SMN1; SMN2LMNAKDM4E | |
| Bromide SCHEMBL8658730 | 0.75 | SMN1; SMN2 (0.44) | CA2TP53SMN1; SMN2LMNAKDM4E | |
| Hydrochloric Acid SCHEMBL11442433 | 0.75 | HTT (0.42) | CA2TP53SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4703496-A1 | ETCHING COMPOSITION COMPRISING AT LEAST ONE IONIC LIQUID AND AT LEAST ONE LACTAMIDE AND PROCESS FOR COATING PLASTIC SURFACES WITH METALS BY USING THE SAME | BASF SE (DE) | 2026-03-04 | — | — | EP | disclosed |
| US-12077631-B2 | Bulk polymerisation of polyoxazolidone | BASF SE (DE) | 2024-09-03 | — | — | US | disclosed |
| CN-112424253-B | Bulk polymerization of polyoxazolidinones | 巴斯夫欧洲公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-3232455-B1 | NONAQUEOUS ELECTROLYTE SOLUTION FOR ELECTRIC DOUBLE LAYER CAPACITORS | OTSUKA CHEMICAL CO LTD (JP) | 2023-10-25 | — | — | EP | disclosed |
| EP-3824012-B1 | BULK POLYMERISATION OF POLYOXAZOLIDONE | BASF SE (DE) | 2022-09-07 | — | — | EP | disclosed |
| CN-110300772-B | Polyoxazolidinones and process for their preparation | 巴斯夫欧洲公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11180603-B2 | Polyoxazolidones and production thereof | BASF SE (DE) | 2021-11-23 | — | — | US | disclosed |
| US-20210253782-A1 | BULK POLYMERISATION OF POLYOXAZOLIDONE | BASF SE (DE) | 2021-08-19 | — | — | US | disclosed |
| EP-3824012-A1 | BULK POLYMERISATION OF POLYOXAZOLIDONE | BASF SE (DE) | 2021-05-26 | — | — | EP | disclosed |
| EP-3583148-B1 | POLYOXAZOLIDONES AND PRODUCTION OF THE SAME | BASF SE (DE) | 2021-03-03 | — | — | EP | disclosed |
| US-20090029887-A1 | USE OF IONIC LIQUIDS FOR THE NONCUTTING FORMING OF METALLIC WORKPIECES | EVONIK GOLDSCHMIDT GMBH (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20090020112-A1 | METHOD FOR BREAKING DOWN CELLULOSE | BASF SE (DE) | 2009-01-22 | — | — | US | disclosed |
| US-20080287684-A1 | Method for Producing Ionic Liquids | BASF SE (DE) | 2008-11-20 | — | — | US | disclosed |
| US-20080269477-A1 | Solvent System Based on Molten Ionic Liquids, Its Production and Use for Producing Regenerated Carbohydrates | BASF SE (DE) | 2008-10-30 | — | — | US | disclosed |
| EP-1966284-A1 | SOLVENT SYSTEM BASED ON MOLTEN IONIC LIQUIDS, ITS PRODUCTION AND USE FOR PRODUCING REGENERATED CARBOHYDRATES | BASF SE (DE) | 2008-09-10 | — | — | EP | disclosed |
| US-20080164440-A1 | Solubility of Cellulose in Ionic Liquids With Addition of Amino Bases | BASF AKTIENGESELLSCHAFT (DE) | 2008-07-10 | — | — | US | disclosed |
| EP-1893651-A2 | SOLUBILITY OF CELLULOSE IN IONIC LIQUIDS WITH ADDITION OF AMINO BASES | BASF SE (DE) | 2008-03-05 | — | — | EP | disclosed |
| US-20080028777-A1 | Novel Pairs Of Working Substances For Absorption Heat Pumps, Absorption Refrigeration Machines And Heat Transformers | BASF AKTIENGESELLSCHAFT (DE) | 2008-02-07 | — | — | US | disclosed |
| WO-2007076979-A1 | SOLVENT SYSTEM BASED ON MOLTEN IONIC LIQUIDS, ITS PRODUCTION AND USE FOR PRODUCING REGENERATED CARBOHYDRATES | BASF SE (DE) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006108861-A2 | SOLUBILITY OF CELLULOSE IN IONIC LIQUIDS WITH ADDITION OF AMINO BASES | BASF AKTIENGESELLSCHAFT (DE) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287684-A1 | Method for Producing Ionic Liquids | HACL2, HAO2, SLC6A12 | CA2 106/4885TP53 3689/4885TAAR1 379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.